The use of driving impairing medicines: a European survey

Abstract

AimTo analyse the consumption of a number of medicines with a known potential for increasing the risk of road traffic accidents in the general population of Europe.MethodsQuestionnaires were distributed through the European Drug Utilization Research Group (EuroDURG) and Post-Innovation Learning through Life-events of drugs (PILLS) networks. A total of 30 countries (the current EU Member States, Iceland, Norway and Switzerland) were asked to supply data on the use of driving impairing medicines for the period 2000–2005, aggregated at the level of the active substance and presented in Defined Daily Doses (DDDs) per 1000 inhabitants per day.ResultsNational utilization data were provided by 12 of the 30 countries. Based on these data, a considerable increase in consumption was only seen for the antidepressants and the selective serotonin reuptake inhibitors. A slight increase, decrease or no increase was seen for the rest of the drugs studied (i.e. opioids, antipsychotics, anxiolytics, hypnotics and sedatives, drugs that are used in addictive disorders and antihistamines). Limitations were encountered when data on driving impairing medicines were compared between countries (e.g. variation in the data sources and providers, population coverage, inclusion of hospital data, use of divergent ATC/DDD versions) and, therefore, a cross-national comparison could not be performed.ConclusionsDuring the study period, trends within countries showed slight to no increase in the consumption of selected medicinal drug groups, with the exception of the antidepressants and the selective serotonin reuptake inhibitors: they showed a remarkable increased use during the study time-frame. Our results illustrate that it is still difficult to perform a valid and comprehensive collection of drug utilization data on driving impairing medicines. Therefore, efforts to harmonize data collection techniques are required and recommended.

Pro-Arrhythmic Potential of Oral Antihistamines (H1): Combining Adverse Event Reports with Drug Utilization Data across Europe

“…High consumption of antihistamines in Norway and Sweden found in our study is in line with a previous drug utilisation survey [ 28 ], which proposed a higher data quality as potential reason for this finding. In this regard, each Country should check for data quality before definitively deciding regulatory strategies (e.g., Lithuania should verify its very low consumption of antihistamines, which may be due to issues of reimbursement restrictions similar to the situation for proton pump inhibitors and statins versus Western European countries [ 29 ]).…”

Trends in drug use among drivers killed in U.S. traffic crashes, 1999–2010

“…Similar trends have been seen in other countries. From 2000-2005, both prescription opioid and benzodiazepine consumption increased 1.5-10% (Ravera et al 2009), whereas methadone (Ravera et al 2009) and barbiturate use remained relatively stable in Europe (Nicholas et al 2012). …”

The Contribution of National Spontaneous Reporting Systems to Detect Signals of Torsadogenicity: Issues Emerging from the ARITMO Project

“…It is worth noting that the signal arose from the German SRS, although no recent drug utilization data are publicly available. A previous European cross-national comparison study on aggregated data (2000–2005 period) reported an unexpected low use of reimbursed antihistamines, which was interpreted in the light of legislation on over-the-counter products [ 29 ]. The latest European drug utilization analysis found that levocetirizine was largely used in France, where the drug represented 53 % of the total defined daily doses of antihistamines [ 12 ].…”